0001493152-26-019085
SEC filingCuprina Holdings reported modest revenue growth of 3.3% to $49.9K in FY2025, but losses widened significantly across all profitability and cash flow metrics — driven by elevated operating expenses and fixed cost structure — with no evidence of operational leverage or margin improvement.
Revenue increased 3.3% to $49.9K in FY2025, driven by higher MEDIFLY product sales in Singapore and Hong Kong. Management explicitly attributes this increase to patient volume expansion in those two markets. However, the absolute level remains extremely low relative to operating costs, underscoring the early-stage commercial profile of the business.
Gross profit improved to -$645 from -$3.0K, a 78.7% improvement in absolute terms. This reflects the fixed nature of cost of revenues — including production staff salaries, facility rent, and equipment depreciation — which do not scale proportionally with modest revenue gains. The gross margin remained negative at -1.3%, confirming no structural improvement in production economics.
Operating income declined to -$4.8M from -$1.6M, and net income fell to -$4.7M from -$1.6M. Management states these increases were due to higher selling, general and administrative expenses and research and development costs — including headcount additions in late 2023 and early 2024, and rising R&D staff compensation. No further breakdown or quantification of expense categories is provided in the authoritative packet, so causality is limited to these broad drivers.
Management states it will continue capital expenditures to meet expected business growth. The $58K spent in FY2025 supports this commitment, though no specific projects, timelines, or geographic targets beyond prior disclosures are substantiated in the financial or business context packets. Liquidity remains constrained, and management notes it may seek additional capital funding to enhance its cash reserve for future investments — signaling continued reliance on external financing rather than self-sustaining operations.